Rep. Robert Bresnahan, Jr. Sells Off Shares of Laboratory Co. of America Holdings (NYSE:LH)

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Laboratory Co. of America Holdings NYSE: LH. In a filing disclosed on May 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in Laboratory Co. of America stock on April 8th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/17/2025.
• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/16/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOG on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of Texas Instruments NASDAQ: TXN on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 4/11/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/10/2025.
• Sold $1,001 - $15,000 in shares of DexCom NASDAQ: DXCM on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Invesco NYSE: IVZ on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Generac NYSE: GNRC on 4/8/2025.

Laboratory Co. of America Stock Down 0.3%

Laboratory Co. of America stock traded down $0.66 during midday trading on Tuesday, reaching $250.28. The stock had a trading volume of 83,481 shares, compared to its average volume of 723,578. Laboratory Co. of America Holdings has a 12 month low of $191.97 and a 12 month high of $258.59. The company has a fifty day moving average price of $233.61 and a two-hundred day moving average price of $237.19. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $20.95 billion, a P/E ratio of 28.38, a PEG ratio of 1.71 and a beta of 0.82.

Laboratory Co. of America (NYSE:LH - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The medical research company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.73 by $0.11. The firm had revenue of $3.35 billion during the quarter, compared to the consensus estimate of $3.41 billion. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. The company's quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the business posted $3.68 earnings per share. As a group, equities analysts expect that Laboratory Co. of America Holdings will post 16.01 EPS for the current fiscal year.

Laboratory Co. of America Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 11th. Shareholders of record on Thursday, May 29th will be issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.15%. Laboratory Co. of America's payout ratio is 33.29%.

Insider Buying and Selling at Laboratory Co. of America

In other Laboratory Co. of America news, EVP Der Vaart Sandra D. Van sold 1,314 shares of the stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $251.30, for a total value of $330,208.20. Following the sale, the executive vice president now owns 2,171 shares of the company's stock, valued at $545,572.30. This trade represents a 37.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CMO Amy B. Summy sold 226 shares of the firm's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $250.40, for a total value of $56,590.40. Following the sale, the chief marketing officer now directly owns 4,544 shares in the company, valued at $1,137,817.60. This trade represents a 4.74% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 10,866 shares of company stock valued at $2,674,576 over the last ninety days. Corporate insiders own 0.84% of the company's stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Citigroup upgraded Laboratory Co. of America from a "neutral" rating to a "buy" rating and upped their price objective for the company from $250.00 to $300.00 in a research note on Tuesday, March 4th. Jefferies Financial Group increased their target price on shares of Laboratory Co. of America from $275.00 to $290.00 and gave the stock a "buy" rating in a research note on Thursday, February 6th. Barclays upped their price objective on shares of Laboratory Co. of America from $240.00 to $250.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. Robert W. Baird raised their price target on Laboratory Co. of America from $253.00 to $267.00 and gave the company an "outperform" rating in a research report on Wednesday, April 30th. Finally, Piper Sandler reissued a "neutral" rating and issued a $280.00 target price (up previously from $260.00) on shares of Laboratory Co. of America in a research note on Tuesday, May 6th. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $270.62.

Institutional Trading of Laboratory Co. of America

Institutional investors have recently bought and sold shares of the stock. Graney & King LLC bought a new stake in Laboratory Co. of America during the 4th quarter valued at $26,000. Golden State Wealth Management LLC increased its holdings in Laboratory Co. of America by 88.1% in the 1st quarter. Golden State Wealth Management LLC now owns 111 shares of the medical research company's stock worth $26,000 after buying an additional 52 shares during the period. North Capital Inc. purchased a new stake in Laboratory Co. of America in the first quarter valued at $27,000. TruNorth Capital Management LLC purchased a new position in shares of Laboratory Co. of America during the 1st quarter valued at approximately $28,000. Finally, Larson Financial Group LLC boosted its position in Laboratory Co. of America by 140.4% during the first quarter. Larson Financial Group LLC now owns 125 shares of the medical research company's stock worth $29,000 after purchasing an additional 73 shares in the last quarter. 95.94% of the stock is currently owned by institutional investors.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.